An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825

被引:150
作者
Gittleman, Haley [1 ]
Lim, Daniel [1 ]
Kattan, Michael W. [2 ]
Chakravarti, Arnab [3 ]
Gilbert, Mark R. [4 ]
Lassman, Andrew B. [5 ,6 ]
Lo, Simon S. [1 ]
Machtay, Mitchell [1 ]
Sloan, Andrew E. [1 ]
Sulman, Erik P. [7 ]
Tian, Devin [1 ]
Vogelbaum, Michael A. [2 ]
Wang, Tony J. C. [5 ,6 ]
Penas-Prado, Marta [7 ]
Youssef, Emad [8 ]
Blumenthal, Deborah T. [9 ]
Zhang, Peixin [10 ]
Mehta, Minesh P. [11 ]
Barnholtz-Sloan, Jill S. [1 ]
机构
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] NIH, Ctr Clin, Bethesda, MD 20892 USA
[5] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA
[6] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Arizona Oncol Serv Fdn, Barrow Neurol Inst, Phoenix, AZ USA
[9] Tel Aviv Univ, Tel Aviv Med Ctr, Tel Aviv, Israel
[10] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA
[11] Miami Canc Inst, Miami, FL USA
关键词
glioblastoma; nomogram; NRG Oncology; RTOG; survival; RANDOMIZED PHASE-III; ADJUVANT TEMOZOLOMIDE; PROMOTER METHYLATION; MULTIFORME; RADIOTHERAPY; CONCOMITANT; PROGNOSIS; TRIAL; BRAIN; EORTC;
D O I
10.1093/neuonc/now208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram to estimate individualized survival probabilities for patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. This analysis included information on 799 (RTOG 0525) and 555 (RTOG 0825) eligible and randomized patients with newly diagnosed GBM and contained the following variables: age at diagnosis, race, gender, Karnofsky performance status (KPS), extent of resection, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status, and survival (in months). Survival was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning analysis, with adjustment for known prognostic factors. The models were developed using the 0525 data and were independently validated using the 0825 data. Models were internally validated using 10-fold cross-validation, and individually predicted 6-, 12-, and 24-month survival probabilities were generated to measure the predictive accuracy and calibration against the actual survival status. A final nomogram was built using the Cox proportional hazards model. Factors that increased the probability of shorter survival included greater age at diagnosis, male gender, lower KPS, not having total resection, and unmethylated MGMT status. A nomogram that assesses individualized survival probabilities (6-, 12-, and 24-mo) for patients with newly diagnosed GBM could be useful to health care providers for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free software for implementing this nomogram is provided: ext-link-type="uri" xlink:href="http://cancer4.case.edu/rCalculator/rCalculator.html.
引用
收藏
页码:669 / 677
页数:9
相关论文
共 23 条
[1]   A nomogram for individualized estimation of survival among patients with brain metastasis [J].
Barnholtz-Sloan, Jill S. ;
Yu, Changhong ;
Sloan, Andrew E. ;
Vengoechea, Jaime ;
Wang, Meihua ;
Dignam, James J. ;
Vogelbaum, Michael A. ;
Sperduto, Paul W. ;
Mehta, Minesh P. ;
Machtay, Mitchell ;
Kattan, Michael W. .
NEURO-ONCOLOGY, 2012, 14 (07) :910-918
[2]   A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999 [J].
Chakrabarti, I ;
Cockburn, M ;
Cozen, W ;
Wang, YP ;
Preston-Martin, S .
CANCER, 2005, 104 (12) :2798-2806
[3]   RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS [J].
CURRAN, WJ ;
SCOTT, CB ;
HORTON, J ;
NELSON, JS ;
WEINSTEIN, AS ;
FISCHBACH, AJ ;
CHANG, CH ;
ROTMAN, M ;
ASBELL, SO ;
KRISCH, RE ;
NELSON, DF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) :704-710
[4]   A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma [J].
Gilbert, Mark R. ;
Dignam, James J. ;
Armstrong, Terri S. ;
Wefel, Jeffrey S. ;
Blumenthal, Deborah T. ;
Vogelbaum, Michael A. ;
Colman, Howard ;
Chakravarti, Arnab ;
Pugh, Stephanie ;
Won, Minhee ;
Jeraj, Robert ;
Brown, Paul D. ;
Jaeckle, Kurt A. ;
Schiff, David ;
Stieber, Volker W. ;
Brachman, David G. ;
Werner-Wasik, Maria ;
Tremont-Lukats, Ivo W. ;
Sulman, Erik P. ;
Aldape, Kenneth D. ;
Curran, Walter J., Jr. ;
Mehta, Minesh P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (08) :699-708
[5]   Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial [J].
Gilbert, Mark R. ;
Wang, Meihua ;
Aldape, Kenneth D. ;
Stupp, Roger ;
Hegi, Monika E. ;
Jaeckle, Kurt A. ;
Armstrong, Terri S. ;
Wefel, Jeffrey S. ;
Won, Minhee ;
Blumenthal, Deborah T. ;
Mahajan, Anita ;
Schultz, Christopher J. ;
Erridge, Sara ;
Baumert, Brigitta ;
Hopkins, Kristen I. ;
Tzuk-Shina, Tzahala ;
Brown, Paul D. ;
Chakravarti, Arnab ;
Curran, Walter J., Jr. ;
Mehta, Minesh P. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4085-+
[6]   Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 [J].
Gorlia, Thierry ;
van den Bent, Martini ;
Hegi, Monika E. ;
Mirimanoff, Rene O. ;
Weller, Michael ;
Cairncross, J. Gregory ;
Eisenhauer, Elizabeth ;
Belanger, Karl ;
Brandes, Alba A. ;
Allgeier, Anouk ;
Lacombe, Denis ;
Stupp, Roger .
LANCET ONCOLOGY, 2008, 9 (01) :29-38
[7]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
[8]  
2-4
[9]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[10]   Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity [J].
Hegi, Monika E. ;
Liu, Lili ;
Herman, James G. ;
Stupp, Roger ;
Wick, Wolfgang ;
Weller, Michael ;
Mehta, Minesh P. ;
Gilbert, Mark R. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4189-4199